IPO performance was mixed last week. In fact, there were three deals that had to be postponed (one was because a company agreed to be acquired).
Here’s a rundown of the offerings:
| company | ticker | return (%) |
| Cempra | CEMP | 0 |
| AVG Technologies | AVG | -18.2 |
| Greenway | GWAY | 32.3 |
| Matador Resources | MTDR | 0 |
| U.S. Silica | SLCA | -5.2 |
Despite the volatility, the average return was still nearly 2%, which shows how one deal can make up for the duds!
For this week, 10 companies plan to hit the markets:
| company (ticker) | terms | description |
| Caesars Entertainment (CZR) | 1.8M shares at $8-$10/share | Major casino operator |
| Cementos Pacasmayo (CPAC) | 20M shares at $12-$13/share | Largest cement producer in Peru |
| Ceres (CERE) | 5M shares at $21-$23/share | Seed producer for bioenergy |
| ChemoCentryx (CCXI) | 4M shares at $14-$16/share | Biotech focused on rheumatoid arthritis and Crohn’s disease |
| EPAM Systems (EPAM) | 7.4M shares at $16-$18/share | Eastern European information-technology service provider |
| FX Alliance (FX) | 5.2M at $14-$16/share | Operates a technology platform for foreign-exchange trading |
| GSE Holding (GSE) | 7M shares at $8-$10/share | Manages waste for mining and other environmental matters |
| Roundys (RNDY) | 18.2M shares at $10-$12/share | Supermarket chain in the Midwest |
| Synacor (SYNC) | 6.8M shares at $9-$11/share | Provided technology systems to cable and telecom companies |
| TVAX Biomedical (TVAX) | 2M shares at $9-$11/share | Biotech focused on cancer treatments |
Tom Taulli runs the InvestorPlace blog IPO Playbook, a site dedicated to the hottest news and rumors about initial public offerings. He also is the author of “The Complete M&A Handbook”, “All About Short Selling” and “All About Commodities.” Follow him on Twitter at @ttaulli or reach him via email. As of this writing, he did not own a position in any of the aforementioned securities.
A long-time follower of the IPO scene, back in 1999 Tom started one of the first sites in the space called WebIPO. It was a place where investors got research as well as access to deals for the dot-com boom. Tom also wrote the top-selling book, Investing in IPOs. In it, he covers all the aspects of analyzing an IPO, such as reading the prospectus, detecting the risk factors and understanding some of the arcane regulations. But don’t worry — if that process is too intimidating for you, thankfully Tom will do the legwork for you right here in the IPO Playbook blog.
Comments are currently unavailable. Please check back soon.